Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.67 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875736 | 0.82 | ADORA2A (0.67) | ADORA2ANUDT1ACHEHSP90AB1 | |
| SCHEMBL4675034 | 0.76 | ADORA2A (0.48) | ADORA2ANUDT1ACHEHSP90AB1APP | |
| SCHEMBL1879097 | 0.76 | ADORA2A (0.58) | ADORA2ANUDT1ACHEDCPS | |
| SCHEMBL1883843 | 0.74 | HSP90AB1 (0.55) | ADORA2AHSP90AB1 | |
| SCHEMBL8925803 | 0.73 | HSP90AB1 (0.75) | ADORA2ANUDT1HSP90AB1 | |
| SCHEMBL3035401 | 0.72 | ADORA2A (0.56) | ADORA2ANUDT1DCPS | |
| SCHEMBL27310325 | 0.71 | ADORA2A (1.00) | ADORA2ANUDT1ACHEDCPS | |
| SCHEMBL4913937 | 0.71 | ADORA2A (0.70) | ADORA2ANUDT1ACHEAPP | |
| SCHEMBL421987 | 0.71 | ADORA2A (1.00) | ADORA2ANUDT1DCPS | |
| SCHEMBL27689624 | 0.71 | ADORA2A (0.64) | ADORA2ANUDT1DCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947696-B2 | heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases | MERCK PATENT GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| CN-101180278-B | 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators | MERCK PATENT GMBH | 2011-05-04 | — | — | CN | disclosed |
| US-20080214586-A1 | 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators | MERCK PATENT GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| CN-101180278-A | 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators | MERCK PATENT GMBH (DE) | 2008-05-14 | — | — | CN | disclosed |
| EP-1881965-A1 | 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS | Merck Patent GmbH (DE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006122631-A1 | 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS | MERCK PATENT GMBH (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214586-A1 | 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators | HSP90AB2P, HSP90AB1, HSP90AA1 | ADORA2A 2930/4885NUDT1 3458/4885ACHE 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.